Accession Number
Approved, Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)

Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) that is selective for interleukin 23 (IL-23). On April 23, 2019 it was approved by the FDA (as SKYRIZI) for the treatment of moderate-to-severe plaque psoriasis in adults who are clinically considered eligible for systemic therapy or phototherapy for psoriasis.Label This drug has been commercialized through collaboration between the German pharmaceutical company, Boehringer Ingelheim, and Abbvie.2

Psoriasis is a chronic inflammatory disease of the skin most commonly characterized by raised, red plaques covered with silver scales in cases of plaque psoriasis. There are several subtypes of psoriasis, however, plaque psoriasis is most prevalent.3 This disease occurs mainly in adults (with a prevalence ranging from 0.91% to 8.5%). Psoriasis has a peak incidence at two age groups: approximately 30–39 years and approximately 60 years of age.3 Depending on disease severity, psoriasis may have significant effects on quality of life and can lead to embarrassment and negative social consequences.4 Risankizumab is a promising drug for the relief of plaque psoriasis and has been shown to be effective in managing the above unpleasant symptoms.Label

Protein chemical formula
Protein average weight
145600.0 Da
>Risankizumab A Chain Sequence
>Risankizumab B Chain Sequence
>Risankizumab C Chain Sequence
>Risankizumab D Chain Sequence
  1. Risankizumab [Link]
Download FASTA Format
  • Risankizumab
  • risankizumab-rzaa
External IDs
655066-01 / ABBV-066 / BI 655066
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
SkyriziSolution90 mgSubcutaneousAbbvie2019-05-13Not applicableCanada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
SkyriziRisankizumab (75 mg/0.83mL) + Isopropyl alcohol (0.70 mL/1mL)Subcutaneous; TopicalAbbVie Inc.2019-04-23Not applicableUs
CAS number



This drug is for the treatment of moderate-to-severe plaque psoriasis in adults who are eligible to receive systemic therapy or phototherapy based on their disease process.Label

Associated Conditions

No formal studies examining pharmacodynamic properties have been completed with risankizumab Label, however, this drug is expected to relieve symptoms of psoriasis by targeting interleukin 23 (IL-23) and preventing the initiation of the inflammatory cascade that is implicated in psoriasis.2

Mechanism of action

Risankizumab acts to prevent the release of pro-inflammatory cytokines and chemokines that often lead to inflammatory skin symptoms, such as redness, pain, and plaques. Risankizumab binds with a high affinity to the p19 subunit of human interleukin 23 (IL-23) cytokine 2, thereby preventing its action on the IL-23 receptor. IL-23 is a cytokine released in the human body that is involved in inflammatory and immune processes, especially in peripheral tissues.2

IL-23 plays a role in polarized type-1 T cell-mediated inflammatory response. Type-1 T cells are found in very high concentrations in psoriasis-affected skin in addition to the blood of psoriasis patients.2 By promoting the action of interferon (IFN)-gamma 7, type-1 T cells increase the expression of many inflammatory genes that induce inflammatory cascades 5. Variants of the gene encoding IL-23 p19 subunit and the IL-23 receptor have been recognized as part of the pathogenesis of plaque psoriasis, rendering IL-23 an ideal target for risankizumab therapy.2

Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more

The absolute bioavailability of risankizumab is estimated at approximately 89% after a dose given by subcutaneous injection. In a clinical study, peak concentration (Cmax) was reached within 3-14 days after beginning risankizumab therapy.Label

In patients diagnosed with psoriasis, estimated risankizumab trough plasma concentrations were found to be 1.72 ± 1.11 at week 16 of treatment and 1.36 ± 0.923 µg/mL at week 52 of treatment, using a predictive pharmacokinetic model.8

The area under the curve (AUC) curve at steady state (study weeks 40–52) was predicted at 344 ± 151 µg/day/mL 8.

Volume of distribution

The approximate volume of distribution at steady state is 11.2 L (34%) in patients diagnosed with plaque psoriasis, but may vary with increased body weight.Label

Protein binding
Not Available

The metabolic pathway of risankizumab has not been characterized. As a humanized IgG1 monoclonal antibody, risankizumab is likely to be catabolized into small peptides and amino acids in the same way as endogenous IgG.Label,9

Route of elimination
Not Available
Half life

The half-life of risankizumab is about 28 days in patients with plaque psoriasis.Label


Systemic clearance is estimated at 0.31 L per day (24%).Label One study found that interindividual clearance for risankizumab varied by 37%.8 Risankizumab clearance is found to decrease with an increase in body weight.Label Despite this tendency, no dose adjustment is advised in overweight patients.Label



In cases of overdose, ensure to monitor the patient for any signs or symptoms of adverse reactions and provide supportive treatment accordingly.Label

Carcinogenesis and mutagenesis

Currently, no studies examining carcinogenic potential or mutagenic potential have been conducted using this drug.Label

Use in pregnancy

There are limited data regarding the administration of risankizumab in pregnant women. An associated risk of major birth defects, miscarriage, or adverse effects on the mother or fetus is not yet established Label. It is important to note, however, that human IgG 6 is known to cross the placenta, and this drug may similarly be transmitted to the growing fetus. Risankizumab belongs to an IgG antibody subclass 6 and likely shares similar properties Label. The Canadian monograph for risankizumab indicates that women of childbearing potential should take adequate contraception during therapy and for at least 20 weeks after the final dose.10

Use during nursing

Currently, there are no available data regarding risankizumab in human milk, its effect on the production of milk, and its effect on a nursing child. Maternal IgG is, however, found to be excreted in human milk. This drug belongs to an IgG subclass, and may share similar properties. 6 The benefits of breastfeeding should be considered in addition to the mother's requirement for risankizumab and any possible risks resulting from nursing while taking this drug, which is likely to be present in human milk.Label

Affected organisms
  • Humans and other mammals
Not Available
Pharmacogenomic Effects/ADRs
Not Available


Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
2-MethoxyethanolThe risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Risankizumab.
9-(N-methyl-L-isoleucine)-cyclosporin AThe risk or severity of adverse effects can be increased when 9-(N-methyl-L-isoleucine)-cyclosporin A is combined with Risankizumab.
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Risankizumab.
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Risankizumab.
AbetimusThe risk or severity of adverse effects can be increased when Abetimus is combined with Risankizumab.
AbituzumabThe risk or severity of adverse effects can be increased when Abituzumab is combined with Risankizumab.
AbrilumabThe risk or severity of adverse effects can be increased when Risankizumab is combined with Abrilumab.
ActeosideThe risk or severity of adverse effects can be increased when Acteoside is combined with Risankizumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Risankizumab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Risankizumab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
No interactions found.


General References
  1. Machado A, Torres T: Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date. Psoriasis (Auckl). 2018 Nov 13;8:83-92. doi: 10.2147/PTT.S165943. eCollection 2018. [PubMed:30519540]
  2. Haugh IM, Preston AK, Kivelevitch DN, Menter AM: Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis. Drug Des Devel Ther. 2018 Nov 12;12:3879-3883. doi: 10.2147/DDDT.S167149. eCollection 2018. [PubMed:30518998]
  3. Di Meglio P, Villanova F, Nestle FO: Psoriasis. Cold Spring Harb Perspect Med. 2014 Aug 1;4(8). pii: 4/8/a015354. doi: 10.1101/cshperspect.a015354. [PubMed:25085957]
  4. Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R: Quality of life in patients with psoriasis. Health Qual Life Outcomes. 2006 Jun 6;4:35. doi: 10.1186/1477-7525-4-35. [PubMed:16756666]
  5. Lew W, Lee E, Krueger JG: Psoriasis genomics: analysis of proinflammatory (type 1) gene expression in large plaque (Western) and small plaque (Asian) psoriasis vulgaris. Br J Dermatol. 2004 Apr;150(4):668-76. doi: 10.1111/j.0007-0963.2004.05891.x. [PubMed:15099362]
  6. Vidarsson G, Dekkers G, Rispens T: IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014 Oct 20;5:520. doi: 10.3389/fimmu.2014.00520. eCollection 2014. [PubMed:25368619]
  7. Ziblat A, Nunez SY, Raffo Iraolagoitia XL, Spallanzani RG, Torres NI, Sierra JM, Secchiari F, Domaica CI, Fuertes MB, Zwirner NW: Interleukin (IL)-23 Stimulates IFN-gamma Secretion by CD56(bright) Natural Killer Cells and Enhances IL-18-Driven Dendritic Cells Activation. Front Immunol. 2018 Jan 17;8:1959. doi: 10.3389/fimmu.2017.01959. eCollection 2017. [PubMed:29403472]
  8. Suleiman AA, Khatri A, Minocha M, Othman AA: Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials. Clin Pharmacokinet. 2019 Mar;58(3):375-387. doi: 10.1007/s40262-018-0704-z. [PubMed:30123942]
  9. Ryman JT, Meibohm B: Pharmacokinetics of Monoclonal Antibodies. CPT Pharmacometrics Syst Pharmacol. 2017 Sep;6(9):576-588. doi: 10.1002/psp4.12224. Epub 2017 Jul 29. [PubMed:28653357]
  10. Skyrizi, Canadian monograph [File]
External Links
AHFS Codes
  • 84:92.00 — Misc. Skin and Mucous Membrane Agents
FDA label
Download (744 KB)

Clinical Trials

Clinical Trials
1CompletedTreatmentHealthy Volunteers1
1RecruitingTreatmentCrohn's Disease (CD) / Ulcerative Colitis1
2CompletedTreatmentAnkylosing Spondylitis (AS)1
2CompletedTreatmentCrohn's Disease (CD)2
2CompletedTreatmentPsoriatic Arthritis2
2RecruitingTreatmentHidradenitis Suppurativa (HS)1
2RecruitingTreatmentSkin Inflammation1
2, 3RecruitingTreatmentUlcerative Colitis1
3Active Not RecruitingTreatmentErythrodermic psoriasis / Generalized Pustular Psoriasis / Psoriasis1
3Active Not RecruitingTreatmentPsoriasis5
3Active Not RecruitingTreatmentPsoriatic Arthritis2
3Not Yet RecruitingTreatmentPalmoplantar Pustulosis (PPP)1
3Not Yet RecruitingTreatmentPsoriasis1
3RecruitingTreatmentCrohn's Disease (CD)2
3RecruitingTreatmentCrohn's Disease (CD) / Novel Coronavirus Infectious Disease (COVID-19)1
3RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19) / Ulcerative Colitis1
4Not Yet RecruitingTreatmentPsoriasis / Psoriasis Vulgaris (Plaque Psoriasis)1
4RecruitingTreatmentPsoriasis Vulgaris (Plaque Psoriasis)1
Not AvailableAvailableNot AvailableCrohn's Disease (CD) / Ulcerative Colitis1


Not Available
Not Available
Dosage forms
SolutionSubcutaneous90 mg
Not Available
Not Available


Not Available
Experimental Properties
Not Available


Not Available
Organic Compounds
Super Class
Organic Acids
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Alternative Parents
Not Available
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available


Protein group
Pharmacological action
General Function
Protein heterodimerization activity
Specific Function
Cytokine that can act as a growth factor for activated T and NK cells, enhance the lytic activity of NK/lymphokine-activated killer cells, and stimulate the production of IFN-gamma by resting PBMC....

  1. Haugh IM, Preston AK, Kivelevitch DN, Menter AM: Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis. Drug Des Devel Ther. 2018 Nov 12;12:3879-3883. doi: 10.2147/DDDT.S167149. eCollection 2018. [PubMed:30518998]
  2. Machado A, Torres T: Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date. Psoriasis (Auckl). 2018 Nov 13;8:83-92. doi: 10.2147/PTT.S165943. eCollection 2018. [PubMed:30519540]
  3. Skyrizi FDA label [File]

Drug created on April 23, 2019 16:37 / Updated on July 12, 2020 18:27

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.